Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients
Tóm tắt
This study aimed to investigate risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients through a meta-analysis. A comprehensive retrieve of Chinese databases China National Knowledge Infrastructure, Wanfang Data, VIP Database and English databases PubMed, ScienceDirect, Embase and Cochrane library was conducted. The studies that meet the requirements for meta-analysis according to inclusion and exclusion criteria were screened and assessed for eligibility. Odds ratio (OR) / Weighted mean difference (WMD) and 95% confidence intervals (95% CIs) or calculable dichotomous and continuous raw data were extracted to perform meta-analysis using random effect model or fixed effect model on the basis of heterogeneity between studies through Review Manager 5.4 software. A total of 14 cross-sectional studies and 3367 cancer patients were included. Meta-analysis results showed that platinum exposure history (OR value 3.13, 95% CI 2.19–4.48, heterogeneity P = 0.26), allergy history (OR value 1.76, 95% CI 1.09–2.85, heterogeneity P = 0.61), platinum free interval (OR value 3.75, 95% CI 2.00–7.06, heterogeneity P = 0.83), dexamethasone premedication dose (OR value 0.28, 95% CI 0.13–0.58, heterogeneity P = 0.21) were significantly correlated to oxaliplatin hypersensitivity reactions. Gender, age, metastasis, combination with bevacizumab, XELOX regimen and cancer types were detected to have no statistically significant effect on oxaliplatin hypersensitivity reactions. Platinum exposure history, allergy history and long platinum-free interval are risk factors of oxaliplatin hypersensitivity reactions. High dexamethasone premedication dose is a protective factor of oxaliplatin hypersensitivity reactions.
Từ khóa
Tài liệu tham khảo
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Grothey A, Goldberg RM (2004) A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 5:2159–2170. https://doi.org/10.1517/14656566.5.10.2159
Rogers BB, Cuddahy T, Briscella C et al (2019) Oxaliplatin: detection and management of hypersensitivity reactions. Clin J Oncol Nurs 23:68–75. https://doi.org/10.1188/19.CJON.68-75
Shepherd GM (2003) Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24:253–262. https://doi.org/10.1385/CRIAI:24:3:253
Toki MI, Saif MW, Syrigos KN (2014) Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opin Drug Saf 13:1545–1554. https://doi.org/10.1517/14740338.2014.963551
Saif MW (2006) Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 5:687–694. https://doi.org/10.1517/14740338.5.5.687
Bano N, Najam R, Qazi F et al (2016) Clinical features of oxaliplatin induced hypersensitivity reactions and therapeutic approaches. Asian Pac J Cancer Prev 17:1637–1641. https://doi.org/10.7314/apjcp.2016.17.4.1637
Aroldi F, Prochilo T, Bertocchi P et al (2015) Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother 27:63–66. https://doi.org/10.1179/1973947814Y.0000000204
Makrilia N, Syrigou E, Kaklamanos I et al (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. https://doi.org/10.1155/2010/207084
Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012. https://doi.org/10.1001/jama.283.15.2008
Rostom A, Dubé C, Cranney A et al (2004) Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. https://www.ncbi.nlm.nih.gov/books/NBK35156/
Ouyang M, Liao T, Lu Y et al (2019) Laparoscopic versus open surgery in lateral lymph node dissection for advanced rectal cancer: a meta-analysis. Gastroenterol Res Pract 2019:7689082. https://doi.org/10.1155/2019/7689082
Hu J, Dong Y, Chen X et al (2015) Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies. Compr Psychiatry 61:78–89. https://doi.org/10.1016/j.comppsych.2015.05.001
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
Li XQ, Yang QL, He GZ et al (2018) Clinical analysis of hypersensitivity reactions to oxaliplatin. Chin J Clin Oncol 45:1268–1271. https://doi.org/10.3969/j.issn.1000-8179.2018.24.055
Du CX, Hong RX, Chen Z et al (2014) Clinical characteristics of oxaliplatin-induced hypersensitivity reactions. Chin J Clin Oncol Rehabil 21:194–197. https://doi.org/10.13455/j.cnki.cjcor.2014.02.21
Shen XP, Liu X, Qian H et al (2013) Clinical analysis of hypersensitivity reaction to oxaliplatin in patients with colorectal cancer. J Chin Oncol 19:623–627. https://doi.org/10.11735/j.issn.1671-170X.2013.08.B008
Zhu QY, Wang YY, Liu XL et al (2017) Clinical analysis of hypersensitivity reactions to oxaliplatin in patients with colorectal cancer. Anti Tumor Pharmacy 7:509–512. https://doi.org/10.3969/j.issn.2095-1264.2017.04.26
Ohta H, Hayashi T, Murai S et al (2017) Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. Cancer Chemother Pharmacol 79:1021–1029. https://doi.org/10.1007/s00280-017-3294-9
Mori Y, Nishimura T, Kitano T et al (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79:136–143. https://doi.org/10.1159/000320613
Kim BH, Bradley T, Tai J et al (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 76:231–238. https://doi.org/10.1159/000205263
Okayama T, Ishikawa T, Sugatani K et al (2015) Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Ther 37:1259–1269. https://doi.org/10.1016/j.clinthera.2015.03.012
Parel M, Ranchon F, Nosbaum A et al (2014) Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 15:1. https://doi.org/10.1186/2050-6511-15-1
Kim MY, Kang SY, Lee SY et al (2012) Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. Asian Pac J Cancer Prev 13:1209–1215. https://doi.org/10.7314/apjcp.2012.13.4.1209
Sohn KH, Kang DY, Kim JY et al (2018) Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure: a prospective observational study. J Allergy Clin Immunol Pract 6(1642–1648):e1642. https://doi.org/10.1016/j.jaip.2017.12.026
Shibata Y, Ariyama H, Baba E et al (2009) Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 14:397–401. https://doi.org/10.1007/s10147-009-0883-6
Yamauchi H, Goto T, Takayoshi K et al (2015) A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care (Engl) 24:111–116. https://doi.org/10.1111/ecc.12156
Seki K, Senzaki K, Tsuduki Y et al (2011) Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 8:210–215. https://doi.org/10.7150/ijms.8.210
Caiado J, Picard M (2014) Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep 14:451. https://doi.org/10.1007/s11882-014-0451-7
Waheed A, Hill T, Dhawan N (2016) Drug allergy. Prim Care 43:393–400. https://doi.org/10.1016/j.pop.2016.04.005
Wheatley LM, Plaut M, Schwaninger JM et al (2015) Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 136(262–271):e262. https://doi.org/10.1016/j.jaci.2015.05.027
Wu HL (2019) Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital. J Oncol Pharm Pract 25:1388–1395. https://doi.org/10.1177/1078155218796190
Lee SY, Kang HR, Song WJ et al (2014) Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol 73:1021–1029. https://doi.org/10.1007/s00280-014-2437-5
Sakaeda T, Kadoyama K, Yabuuchi H et al (2011) Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 8:332–338. https://doi.org/10.7150/ijms.8.332
Yoshida Y, Hirata K, Matsuoka H et al (2015) A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Drug Des Devel Ther 9:6067–6073. https://doi.org/10.2147/DDDT.S94901
Kidera Y, Satoh T, Ueda S et al (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 16:244–249. https://doi.org/10.1007/s10147-010-0170-6
Brandi G, Pantaleo MA, Galli C et al (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477–481. https://doi.org/10.1038/sj.bjc.6601155
Syrigou EI, Karapanagiotou EM, Alamara CV et al (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8:106–109. https://doi.org/10.3816/CCC.2009.n.017
Polyzos A, Tsavaris N, Gogas H et al (2009) Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 76:36–41. https://doi.org/10.1159/000178163
Lenz G, Hacker UT, Kern W et al (2003) Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 14:731–733. https://doi.org/10.1097/00001813-200310000-00007
Simons FE, Ardusso LR, Dimov V et al (2013) World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 162:193–204. https://doi.org/10.1159/000354543